46 results
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
and development (“R&D”) Expenses
The following table sets forth our R&D expenses by product development program for the three months ended March 31, 2024 … -197)
Other
Total R&D expenses
Total R&D expenses decreased by $1.3 million, or 25%, from $5.3 million in the three months ended March 31, 2023 to $4.0
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
Total research and development (R&D) expenses decreased by $1.3 million, or 25%, from $5.3 million in the first quarter of 2023 to $4.0 million … in the first quarter of 2024. The decrease was primarily due to a $1.8 million reduction in R&D expenses for etigilimab, partially offset by increases
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
or other assessments and our ability to claim R&D tax credits or other reliefs.
Fundraising and business development efforts may divert our management … that carries out extensive research and development (“R&D”) activities, we benefit from the U.K. HM Revenue and Customs (“HMRC”) small and medium
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
to $17.4 million in 2023. The decrease was primarily due to a $12.4 million reduction in R&D expenses for etigilimab, partially offset by an increase
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
product candidates.
Research and Development (“R&D”) Expenses
Research and development expenses include:
employee-related expenses, such as salaries … and development activities, we benefit from the U.K. R&D small or medium-sized enterprise tax credit regime and are able to surrender some of our trading
6-K
EX-99.3
qyq hkrx2
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
lhv4tkf0gyh w52y
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
644fn8 f5y620x9
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
ihoo2o7dzlxzdd9kn69
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
58mhbo
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
pfb ce5lz
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
s5www7r
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
CORRESP
bsnl40u0aqbhf
19 Aug 22
Correspondence with SEC
12:00am
6-K
EX-99.1
v1yh 71xiyr9o4z0ypr
31 Mar 22
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
4:18pm
6-K
h7imm1pseh45p 2i
14 Mar 22
Current report (foreign)
10:05am
6-K
EX-99.1
sdfuwbld8 1ucom
14 Mar 22
Current report (foreign)
10:05am
6-K
EX-99.2
m8lgb x7m21mx
2 Nov 21
Current report (foreign)
4:16pm